MANCHESTER, Conn., Dec. 20, 2010 (GLOBE NEWSWIRE) -- Charter Medical, a subsidiary of Lydall, Inc. (NYSE:LDL) announced today that it has received 510(k) clearance on its next generation Cell Freeze® Cryogenic Storage Containers for Hematopoietic Progenitor Cells (HPC's). The issuance of the clearance by the U.S. Food and Drug Administration (FDA) allows Charter Medical to begin marketing the newly designed and expanded product offering for cryogenic storage, preservation, and transfer of HPC's. This next generation of containers offers a broader size range from 50 mL to 750 mL, redesigned configuration for easier use, and the same unique film as its predecessor product.
